Brain imaging for Alzheimer's disease using a new PET probe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the diagnostic potential of the PET probe [18F]CSF-23 for assessing CSF1R expression in the brains of individuals with Alzheimer's disease. By utilizing positron emission tomography (PET) imaging, the study seeks to determine the role of CSF1R in Alzheimer's and to assess the safety and effectiveness of this imaging technique. Participants will include cognitively normal individuals as controls to establish baseline measurements. The study will focus on the correlation between CSF1R expression and Alzheimer's pathology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Non-diseased controls:

  1. Between 60 and 80 years of age; gender is not limited.
  2. Cognitively normal as determined by the investigator through testing, with an MMSE score greater than 25 and no cognitive domain impairment. They had a negative Aβ image.
  3. No neurological diseases, major chronic diseases, malignant tumors, or acute infectious diseases, as determined by the investigator.
  4. Written informed consent must be signed by the subject or his/her legal guardian or caregiver.
  5. Blood routine: white blood cell count (WBC) 4\~10×109/L; platelet (PLT) 100\~300×109/L; hemoglobin (HB) 120\~160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; hepatic function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range; Electrocardiogram: no significant abnormalities.
  6. No neurological diseases, major chronic diseases, malignant tumors, or acute infectious diseases, as confirmed by the investigator; no family history of neurodegenerative movement disorders, and no family history of neurological disorders related to movement disorders.
  7. Willingness and ability to cooperate with all programs of this study.

AD patients:

1. Age between 60 and 80 years old; gender is not limited.
2. Patients meet the 2011 NIA-AA diagnostic criteria for red AD patients and have positive Aβ images.
3. Brain MRI supported the diagnosis of AD and there was no evidence of other neurological diseases.
4. No neurological diseases, major chronic diseases, malignant tumors or acute infectious diseases, etc., as confirmed by the investigator.
5. Written informed consent must be signed by the subject or his/her legal guardian or caregiver.
6. Blood routine: white blood cell count (WBC) 4\~10×109/L; platelet (PLT) 100\~300×109/L; hemoglobin (HB) 120\~160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; hepatic function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range; ECG: no significant abnormalities.
7. No neurological diseases, major chronic diseases, malignant tumors, or acute infectious diseases, as confirmed by the investigator; no family history of neurodegenerative movement disorders, and no family history of neurological disorders related to movement disorders.
8. Willingness and ability to cooperate with all programs of this study.

Exclusion Criteria:

* Subjects meeting any of the following criteria will be excluded from the study:

  1. Severe hepatic or renal insufficiency;
  2. Participation in other research protocols or clinical care within the past year, in addition to the radiation exposure expected from participation in this clinical study, which has resulted in radiation exposure in excess of an effective dose of 50 mSv.
  3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
  4. History of serious surgery in the last month.
  5. Participation in other clinical trials during the same period.

Where it's running

• Huashan Hospital
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Fang Xie, PhD — Huashan Hospital
• Study coordinator: Yihui Guan, MD
• Email: guanyihui@hotmail.com
• Phone: 13764308300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• Following memory decline in Alzheimer disease

  This project will use 7T MRI, EEG, blood and stool samples, and memory tests to see if they can track memory decline in people over 55 with Alzheimer's disease or mild cognitive impairment.

  Recruiting Norwegian University of Science and Technology · Trondheim, Trønderlag · NCT07118137

• Using saliva and extracellular vesicles to diagnose neurodegenerative diseases

  This study is testing a new way to diagnose neurodegenerative diseases like Alzheimer's and Parkinson's by analyzing saliva samples to see if it can help identify these conditions earlier and tailor treatments for patients.

  Recruiting at 5 sites Fondazione Don Carlo Gnocchi ETS · Florence, FI and 4 other locations · NCT06869135

• Establishing a cohort for Alzheimer's disease research in China

  This study is trying to understand how brain scans and other health markers relate to Alzheimer's disease in both people with and without cognitive issues in China, to help find ways to detect and prevent the disease early.

  Recruiting Huashan Hospital · Shanghai · NCT06827678

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

• Effects of speech-language intervention on bilingual speakers with primary progressive aphasia

  This study tests if special speech therapy designed for bilingual people can help those with primary progressive aphasia communicate better in both of their languages.

  Recruiting at 2 sites University of Texas at Austin · Austin, Texas and 2 other locations · NCT05741853

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.